Holen Sie sich die Stockscreener-App
2.51
3.46%
-0.09
Handel nachbörslich:
2.47
-0.04
-1.59%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt FBIO?
Forum
Prognose
Aktiensplit
Fortress Biotech Inc Aktie (FBIO) Neueste Nachrichten
FBIO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Fortress Biotech Inc (FBIO) Stock Price, Trades & News - GuruFocus
FBIO PE Ratio & Valuation, Is FBIO Overvalued - Intellectia AI
Fortress Biotech Inc reports results for the quarter ended December 31Earnings Summary - TradingView
FBIO SEC FilingsFortress Biotech Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Fortress Biotech (FBIO) CFO adds 2,967 ESPP shares in exempt grant - Stock Titan
Fortress Biotech (NASDAQ:FBIO) Issues Quarterly Earnings Results, Misses Estimates By $0.32 EPS - MarketBeat
Fortress Biotech: Q4 Earnings Snapshot - marketscreener.com
Fortress Biotech 2025 10-K: Revenue $63.3M, GAAP net loss $(32.9)M - TradingView
Fortress Biotech (NASDAQ: FBIO) boosts cash with PRV sale, royalties - Stock Titan
Fortress Biotech (NASDAQ: FBIO) turns 2025 profit with $205M PRV sale and new royalties - Stock Titan
Fortress Biotech Inc expected to post earnings of 11 cents a shareEarnings Preview - TradingView
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights - marketscreener.com
フォートレス・バイオテック、2025年度財務実績及び直近の企業ハイライトを報告 - Moomoo
Avenue Therapeutics Focuses on Neurologic Disease Therapies with ATX-04 and IV Tramadol as Key Product Candidates in 2026 - Minichart
Fortress Biotech Subsidiary Sells Rare Disease Priority Voucher for $205M - nationaltoday.com
Fortress Biotech Gains Cash From Voucher Sale, Simplifies Capital - TipRanks
Fortress Biotech (NASDAQ: FBIO) targets $100M+ from Cyprium PRV sale - Stock Titan
Cyprium Therapeutics sells rare disease priority review voucher for $205 million - StreetInsider
Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million - ChartMill
Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million - Bitget
Why (FBIOP) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Aug Spikes: How do insiders feel about Fortress Biotech IncFed Meeting & Expert Curated Trade Ideas - baoquankhu1.vn
Fortress Biotech (NASDAQ:FBIO) Lowered to Hold Rating by Wall Street Zen - marketbeat.com
Fortress Biotech Inc Stock: Business Model, Pipeline Progress, and Investor Considerations in Biotec - AD HOC NEWS
Fortress Biotech Inc Stock: Journey Medical's Strong 2025 Results Highlight Growth Potential in Derm - AD HOC NEWS
Portfolio Recap: How does Fortress Biotech Inc score in quality rankingsOptions Play & Safe Entry Point Alerts - baoquankhu1.vn
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights - GlobeNewswire
Portfolio Shifts: Can Fortress Biotech Inc deliver alphaQuarterly Earnings Summary & Smart Money Movement Alerts - baoquankhu1.vn
Fortress Biotech (FBIO) Projected to Post Quarterly Earnings on Monday - MarketBeat
Fortress Biotech to Receive $205M as Cyprium Agrees Sale of Rare Pediatric Disease Priority Review Voucher - MSN
Buyback Watch: How liquid is Fortress Biotech Inc stock2026 Recap & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Fortress Biotech (FBIO) CEO Lindsay Rosenwald reports 20.7% ownership in 13D/A - Stock Titan
Fortress Biotech (FBIO) Executive Vice Chairman granted 475,424 restricted shares - Stock Titan
FORTRESS BIOTECH INC 9.375% Cumulative Redeemable Preferred Stock Series A USD25.00 (FBIOP.US) will release its earnings report after the market closes on March 25. - 富途牛牛
Mustang Bio, Inc. 2025 Annual Report: Clinical-Stage Biopharmaceutical Pipeline, Risks, and Regulatory Overview - Minichart
Mustang Bio (NASDAQ: MBIO) details GBM pipeline, Orphan status and cash - Stock Titan
Fortress Biotech (NASDAQ:FBIO) Cut to "Hold" at Zacks Research - MarketBeat
Fortress Biotech (NASDAQ:FBIO) Shares Pass Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Understanding Momentum Shifts in (FBIOP) - Stock Traders Daily
Macro Review: How do insiders feel about Fortress Biotech IncMarket Movers & Verified Momentum Stock Alerts - baoquankhu1.vn
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026 - GlobeNewswire
Quarterly Earnings: Should value investors consider Fortress Biotech Inc2026 Growth vs Value & Consistent Profit Trade Alerts - baoquankhu1.vn
Fortress Biotech Inc Stock (ISIN: US32015L1035) Faces Short Interest Pressure Amid Biotech Sector Vo - AD HOC NEWS
Fortress Biotech (NASDAQ:FBIO) Stock Price Passes Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Swing Trade: How do insiders feel about Fortress Biotech IncCEO Change & Daily Technical Forecast Reports - baoquankhu1.vn
Avoiding Lag: Real-Time Signals in (FBIOP) Movement - Stock Traders Daily
Aug Sectors: How do insiders feel about Fortress Biotech IncMarket Performance Recap & Technical Entry and Exit Tips - baoquankhu1.vn
Aug Opening: What are the risks of holding Fortress Biotech IncJuly 2025 PreEarnings & Risk Controlled Swing Alerts - baoquankhu1.vn
Why Is Fortress Biotech Stock Falling Today? - Stocktwits
FBIO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Weekly Trades: Will Fortress Biotech Inc outperform during market ralliesTreasury Yields & Technical Pattern Recognition Alerts - baoquankhu1.vn
Gap Down: Will Fortress Biotech Inc outperform during market ralliesNew Guidance & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Fortress Biotech (NASDAQ:FBIO) Stock Passes Above Two Hundred Day Moving AverageHere's Why - MarketBeat
Fortress Biotech (NASDAQ:FBIO) Stock Passes Above Two Hundred Day Moving Average – Here’s Why - Defense World
FBIO Should I Buy - Intellectia AI
Discipline and Rules-Based Execution in FBIOP Response - Stock Traders Daily
Fortress Biotech’s Cyprium enters agreement to sell PRV for $205M - Yahoo Finance
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):